Acacia Pharma Group plc Notice Of Full Year 2020 Results

 
TIDMACPH 
 
 
   Acacia Pharma to Report its Results for the Full Year 2020 and Provide a 
Business Update on 29 March 2021 
 
 
 
   Cambridge, UK and Indianapolis, US -- 18 March 2021, 08:00 CET: Acacia 
Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a 
commercial stage biopharmaceutical company focused on developing and 
commercializing novel products to improve the care of patients 
undergoing serious medical treatments such as surgery, invasive 
procedures, or chemotherapy, announces that it will report its results 
for the full year 2020 and provide an update on progress with the 
commercialization of BARHEMSYS(R) and BYFAVO(TM) on Monday, 29 March 
2021 at 07.00 CEST. 
 
   A presentation by Acacia Pharma's senior management team will be webcast 
live the same day at 14.30 CEST (08.30 EST). 
 
   The webcast can be accessed from 
https://www.globenewswire.com/Tracker?data=SLPS7CKhbOXlINx9yToCnmn8dRRT2mXBhB5z_knAv3qcK9ixDRtqA3w76T_pT3oWeketBMFgj_3sOHC9kYscZlwN0FVM6OkG2EJKQa5UEC8= 
www.acaciapharma.com and a recording will be available after the event. 
 
   The results report and presentation will be available at 
https://www.globenewswire.com/Tracker?data=SLPS7CKhbOXlINx9yToCnmn8dRRT2mXBhB5z_knAv3rKUtALNSzb1b8tkt2JOIWjYzTk9UbQ_vk1BgVTIOh5i8F6p62k63plJpw7KtHA6Cg= 
www.acaciapharma.com in the Investors section from 07.00 CEST the same 
day. 
 
   ### 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                              Dible 
 [phone] / [phone]                Citigate Dewe Rogerson 
 mailto:[e-mail] [e-mail]   [phone] 
                                                  mailto:[e-mail] 
                                                  [e-mail] 
-----------------------------------------------  --------------------------------------------- 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    [phone] 
 [phone]                                  mailto:[e-mail] 
 mailto:[e-mail]              [e-mail] 
 [e-mail] 
-----------------------------------------------  --------------------------------------------- 
 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
marketed in the US for the management of postoperative nausea & vomiting 
(PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centered in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   https://www.globenewswire.com/Tracker?data=SLPS7CKhbOXlINx9yToCnmn8dRRT2mXBhB5z_knAv3oOXDBZuPOxEpOotqqjnjh94_z7tDSDH-MiRog-T_xG14emxaJGSQqaePYDi6hfliE= 
www.acaciapharma.com 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 18, 2021 03:00 ET (07:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.